-
Something wrong with this record ?
Substrate Specificity and Biochemical Characteristics of an Engineered Mammalian Chondroitinase ABC
PM. Warren, JW. Fawcett, JCF. Kwok
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2016
PubMed Central
from 2016
Europe PubMed Central
from 2016
ROAD: Directory of Open Access Scholarly Resources
from 2016
- Publication type
- Journal Article MeSH
Chondroitin sulfate proteoglycans inhibit regeneration, neuroprotection, and plasticity following spinal cord injury. The development of a second-generation chondroitinase ABC enzyme, capable of being secreted from mammalian cells (mChABC), has facilitated the functional recovery of animals following severe spinal trauma. The genetically modified enzyme has been shown to efficiently break down the inhibitory extracellular matrix surrounding cells at the site of injury, while facilitating cellular integration and axonal growth. However, the activity profile of the enzyme in relation to the original bacterial chondroitinase (bChABC) has not been determined. Here, we characterize the activity profile of mChABC and compare it to bChABC, both enzymes having been maintained under physiologically relevant conditions for the duration of the experiment. We show that this genetically modified enzyme can be secreted reliably and robustly in high yields from a mammalian cell line. The modifications made to the cDNA of the enzyme have not altered the functional activity of mChABC compared to bChABC, ensuring that it has optimal activity on chondroitin sulfate-A, with an optimal pH at 8.0 and temperature at 37 °C. However, mChABC shows superior thermostability compared to bChABC, ensuring that the recombinant enzyme operates with enhanced activity over a variety of physiologically relevant substrates and temperatures compared to the widely used bacterial alternative without substantially altering its kinetic output. The determination that mChABC can function with greater robustness under physiological conditions than bChABC is an important step in the further development of this auspicious treatment strategy toward a clinical application.
Department of Physiology Development and Neuroscience University of Cambridge Cambridge CB2 0PY U K
School of Biomedical Sciences Faculty of Biological Sciences University of Leeds Leeds LS2 9JT U K
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21017940
- 003
- CZ-PrNML
- 005
- 20210729104210.0
- 007
- ta
- 008
- 210726s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acsomega.0c06262 $2 doi
- 035 __
- $a (PubMed)34056277
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Warren, Philippa M $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, U.K $u Wolfson Centre for Age Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Campus, London Bridge, London SE1 1UL, U.K $u Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 0PY, U.K
- 245 10
- $a Substrate Specificity and Biochemical Characteristics of an Engineered Mammalian Chondroitinase ABC / $c PM. Warren, JW. Fawcett, JCF. Kwok
- 520 9_
- $a Chondroitin sulfate proteoglycans inhibit regeneration, neuroprotection, and plasticity following spinal cord injury. The development of a second-generation chondroitinase ABC enzyme, capable of being secreted from mammalian cells (mChABC), has facilitated the functional recovery of animals following severe spinal trauma. The genetically modified enzyme has been shown to efficiently break down the inhibitory extracellular matrix surrounding cells at the site of injury, while facilitating cellular integration and axonal growth. However, the activity profile of the enzyme in relation to the original bacterial chondroitinase (bChABC) has not been determined. Here, we characterize the activity profile of mChABC and compare it to bChABC, both enzymes having been maintained under physiologically relevant conditions for the duration of the experiment. We show that this genetically modified enzyme can be secreted reliably and robustly in high yields from a mammalian cell line. The modifications made to the cDNA of the enzyme have not altered the functional activity of mChABC compared to bChABC, ensuring that it has optimal activity on chondroitin sulfate-A, with an optimal pH at 8.0 and temperature at 37 °C. However, mChABC shows superior thermostability compared to bChABC, ensuring that the recombinant enzyme operates with enhanced activity over a variety of physiologically relevant substrates and temperatures compared to the widely used bacterial alternative without substantially altering its kinetic output. The determination that mChABC can function with greater robustness under physiological conditions than bChABC is an important step in the further development of this auspicious treatment strategy toward a clinical application.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Fawcett, James W $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, U.K $u Centre for Reconstructive Neuroscience, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic
- 700 1_
- $a Kwok, Jessica C F $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, U.K $u Centre for Reconstructive Neuroscience, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic $u School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, U.K
- 773 0_
- $w MED00207589 $t ACS omega $x 2470-1343 $g Roč. 6, č. 17 (2021), s. 11223-11230
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34056277 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104209 $b ABA008
- 999 __
- $a ind $b bmc $g 1676472 $s 1138382
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 6 $c 17 $d 11223-11230 $e 20210419 $i 2470-1343 $m ACS omega $n ACS Omega $x MED00207589
- LZP __
- $a Pubmed-20210726